Gout is the most common inflammatory arthritis worldwide. Although effective treatments exist to eliminate sodium urate crystals and to 'cure' the disease, the management of gout is often suboptimal. This article reviews available treatments, recommended best practice and barriers to effective care, and how these barriers might be overcome. To optimize the management of gout, health professionals need to know not only how to treat acute attacks but also how to up-titrate urate-lowering therapy against a specific target level of serum uric acid that is below the saturation point for crystal formation. Current perspectives are changing towards much earlier use of urate-lowering therapy, even at the time of first diagnosis of gout. Holistic assessment and patient education are essential to address patient-specific risk factors and ensuring adherence to individualized therapy. Shared decision-making between a fully informed patient and practitioner greatly increases the likelihood of curing gout.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/nrrheum.2014.32 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Gout, a common chronic disease, is characterized by the formation and deposition of monosodium urate (MSU) crystal deposition in articular and nonarticular structures. Osteoarthritis (OA), the most prevalent type of arthritis, is a progressive degenerative joint disease. Previous clinical studies have reported that gout frequently affects OA joints; however, the underlying mechanism remains unidentified.
View Article and Find Full Text PDFTargeting uric acid: a promising intervention against oxidative stress and neuroinflammation in neurodegenerative diseases.
Cell Commun Signal
January 2025
Department of Anesthesiology, Cheeloo College of Medicine, Qilu Hospital (Qingdao), Shandong University, 758 Hefei Road, Qingdao, China.
Oxidative stress and neuroinflammation are recognized as key factors in the development of neurodegenerative diseases, yet effective interventions and biomarkers to address oxidative stress and neuroinflammation in these conditions are limited. Uric acid (UA), traditionally associated with gout, is now gaining prominence as a potential target in neurodegenerative diseases. Soluble UA stands out as one of the most vital antioxidant compounds produced by the human body, accounting for up to 55% of the extracellular capacity to neutralize free radicals.
View Article and Find Full Text PDFAssociation between obstructive sleep apnea and hyperuricemia/gout in the general population: a cross-sectional study.
BMC Musculoskelet Disord
January 2025
Department of Internal Medicine, Division of Rheumatology, Soonchunhyang University Seoul Hospital, Soonchunhyang University School of Medicine, Seoul, South Korea.
Background: Obstructive sleep apnea (OSA) is linked to various health conditions, including cardiovascular diseases and metabolic disorders. Hyperuricemia and gout may be associated with OSA, but large-scale studies on this are limited. This study aimed to investigate the association between hyperuricemia/gout and OSA using data from the Korea National Health and Nutrition Survey (KNHANES).
View Article and Find Full Text PDFRelationship between gout flare states and patient-reported outcomes following allopurinol initiation.
Arthritis Care Res (Hoboken)
January 2025
University of Auckland, Auckland, New Zealand.
Article Synopsis
- Gout flares are crucial indicators of the disease's impact, with specific maximum flare counts linked to acceptable symptom states (PASS) and low disease activity (LDA).
- A study analyzed data from 179 gout patients over 12 months, focusing on flare occurrences and assessing their impact on patient-reported outcomes, including quality of life and illness perception.
- Results showed that while many participants achieved either PASS or LDA, increased flare frequency correlated with higher negative impacts on patients, emphasizing the need for effective flare prevention strategies in gout management.
Healthcare burden of public hospital gout admissions in New South Wales, Australia.
Intern Med J
December 2024
Department of Rheumatology, Westmead Hospital, Western Sydney Local Health District, Sydney, New South Wales, Australia.
Background And Aims: In New Zealand, the Māori and Pacific Islander population has a higher rate of hospital admissions for gout; however, we lack data for these population groups who reside in Australia. This study examined the pattern of hospital gout admissions in New South Wales (NSW), the most populous state of Australia, with a particular focus on the Māori and Pacific Islander population.
Methods: This was a retrospective cohort study exploring the pattern of gout admissions in NSW public hospitals in the financial years 2017/2018 to 2019/2020.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!